CLINICAL TRIALS PROFILE FOR ACETYLCYSTEINE LYSINE
✉ Email this page to a colleague
All Clinical Trials for ACETYLCYSTEINE LYSINE
Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
---|---|---|---|---|---|---|
NCT00799578 ↗ | A Preliminary Study to Evaluate Cysteamine Therapy in Human Subjects With Non-Alcoholic Steatohepatitis (NASH) | Completed | Raptor Pharmaceuticals Corp. | Phase 1/Phase 2 | 2008-10-01 | The purpose of this study is to determine whether cysteamine will effectively reduce or reverse the biologic markers of steatohepatitis in patients. |
NCT00799578 ↗ | A Preliminary Study to Evaluate Cysteamine Therapy in Human Subjects With Non-Alcoholic Steatohepatitis (NASH) | Completed | Joel Lavine | Phase 1/Phase 2 | 2008-10-01 | The purpose of this study is to determine whether cysteamine will effectively reduce or reverse the biologic markers of steatohepatitis in patients. |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for ACETYLCYSTEINE LYSINE
Condition Name
Clinical Trial Locations for ACETYLCYSTEINE LYSINE
Trials by Country
Clinical Trial Progress for ACETYLCYSTEINE LYSINE
Clinical Trial Phase
Clinical Trial Sponsors for ACETYLCYSTEINE LYSINE
Sponsor Name